Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed, Inc.    ABMD

ABIOMED, INC.

(ABMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abiomed : to Host a Virtual Meeting to Discuss New Clinical Data Presented at TCT Connect

10/15/2020 | 08:31am EST

Abiomed, Inc. (NASDAQ: ABMD) announced it will host a virtual investor meeting on Tuesday, October 20, 2020 at 8:00 a.m. EDT to review new clinical data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The virtual meeting will include a presentation from Chuck A. Simonton, MD, Vice President and Chief Medical Officer, focused on the latest data from the PROTECT III and Restore EF studies of Impella supported high-risk PCI patients. The meeting will also include an interactive question and answer session with Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer.

Investors may join the virtual meeting by logging on to https://info.abiomed.com/TCT-Investor or visiting the investor section of the company’s website at www.abiomed.com.

A replay of the October 20 virtual investor meeting will be available on the investor section of www.abiomed.com after the event.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


© Business Wire 2020
All news about ABIOMED, INC.
11/11ABIOMED : to Hold Fireside Chat at the Stephens Annual Investment Conference 202..
BU
11/06ABIOMED INC : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
11/06ABIOMED : First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Hear..
AQ
11/05ABIOMED : First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Hear..
BU
10/30ABIOMED : Announces Q2 FY 2021 Revenue of $210 Million, Up 27% over Q1 FY 2021 a..
AQ
10/29ABIOMED : First Patients Treated with the World's Smallest Heart Pump, the 9Fr I..
AQ
10/29ABIOMED INC : Results of Operations and Financial Condition, Financial Statement..
AQ
10/29ABIOMED : Fiscal 2Q Earnings Snapshot
AQ
10/29ABIOMED : Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 a..
BU
10/28ABIOMED : First Patients Treated with the World's Smallest Heart Pump, the 9Fr I..
BU
More news
Financials (USD)
Sales 2021 834 M - -
Net income 2021 206 M - -
Net cash 2021 549 M - -
P/E ratio 2021 59,3x
Yield 2021 -
Capitalization 12 040 M 12 040 M -
EV / Sales 2021 13,8x
EV / Sales 2022 11,2x
Nbr of Employees 1 536
Free-Float 92,2%
Chart ABIOMED, INC.
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 312,40 $
Last Close Price 268,21 $
Spread / Highest target 36,1%
Spread / Average Target 16,5%
Spread / Lowest Target -19,1%
EPS Revisions
Managers
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer & Senior Vice President
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sieß Chief Technology Officer & Vice President
Charles A. Simonton Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED, INC.57.22%12 120
THERMO FISHER SCIENTIFIC37.29%178 763
DANAHER CORPORATION47.09%160 375
INTUITIVE SURGICAL, INC.23.61%85 902
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.91.59%64 178
EDWARDS LIFESCIENCES CORPORATION8.70%52 683